| 引用本文: | 盛文彬,李亚芬,郑绪阳.卡介苗多糖核酸注射液预防过敏性紫癜复发的82例临床观察[J].中国现代应用药学,2010,27(11):1051-1053. |
| .Clinical Study on Treatment of 82 Patients with the Recurrence of Henoch-Schonle in Purpura by Bacille Calmette-guerin Polysaccharide Nucleic Acid[J].Chin J Mod Appl Pharm(中国现代应用药学),2010,27(11):1051-1053. |
|
|
| 摘要: |
| 目的 观察卡介苗多糖核酸注射液预防过敏性紫癜(HSP)复发的临床效果及相关因素分析。方法 82例HSP患儿随机分为治疗组46例和对照组36例，33例健康儿童作为正常对照组。对照组常规治疗，治疗组加卡介苗多糖核酸注射液肌注，0.5 mg，1周2次，疗程为3个月。观察1年内病情的反复、复发率及测定治疗前、治疗3个月后血CD3+，CD4+，CD8+，白介素-2(IL-2)，γ-干扰素(IFN-γ)，IgA水平。结果 HSP患儿治疗前血CD3+，CD4+，IL-2，IFN-γ水平均低于正常对照组(P<0.01)，IgA明显上升(P<0.01)，CD8+细胞水平各组间无明显差异(P>0.05)，观察3个月后复查血CD3+，CD4+，CD8+，IL-2，IFN-γ，IgA水平，发现治疗组的各项指标恢复较对照组明显(P<0.05或<0.01)，1年复发率明显下降(P<0.05)。结论 卡介苗多糖核酸能调节HSP患儿免疫功能，能有效降低复发率。 |
| 关键词: 过敏性紫癜 卡介苗多糖核酸注射液 细胞免疫 免疫球蛋白 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Clinical Study on Treatment of 82 Patients with the Recurrence of Henoch-Schonle in Purpura by Bacille Calmette-guerin Polysaccharide Nucleic Acid |
|
SHENG Wenbina LI Yafenb ZHENG Xuyanga
|
| Abstract: |
| OBJECTIVE To observe the clinical effect of bacille calmette-guerin polysaccharide nucleic acid (BCG-PSN) for prevention of the recurrence of Henoch-Schonlein purpura(HSP) and analyze its related factors. METHODS Eighty-two children were divided randomly into the treatment group (46) and the control group (36), the former was treated with common therapy and BCG-PSN (0.5mg, twice a week for 3 months, im), and the latter was treated only with common therapy. Another 33 healthy children were served as normal control group. Observe the rate of recurrence in hospitalization in a year, and determined the level of CD3+, CD4+, CD8+, IL-2, IFN-γ, IgA before and after 3 months′ treatment. RESULTS Before treatment, the level of CD3+, CD4+, IL-2, IFN-γ in the treatment group were lower than those in normal control group (P<0.01), and the level of IgA was higher than those in normal control group(P<0.01). Three months after treatment, the level of CD3+, CD4+, CD8+, IL-2, IFN-γ, IgA in the treatment group recovery better than those in the control group significantly (P<0.01 or P<0.05), there was no difference between the treatment group and the normal control group (P<0.05). The rate of recurrence in the treatment group was lower than that in the control group in a year (P<0.05). CONCLUSION BCG-PSN can adjust the immune function and lower the recurrence of HSP. |
| Key words: Henoch-Schonlein purpura bacilli calmette-guerin polysaccharide nucleic acid cellular immunity immunoglobulin |
